Skip to content
Open access

Re-evaluating the role of adjuvant chemotherapy after neoadjuvant chemotherapy in resected gastric cancer

Oct 2026 · The Oncologist · Vol 31 · 0 citations · 20 references
Medicine

Abstract

Abstract Background Perioperative chemotherapy is the standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients with resectable GC who did vs did not receive AC after NAC and surgery. Methods A retrospective study was conducted at a tertiary cancer center to evaluate survival differences in patients who did vs did not receive AC. Patients with resected GC who received NAC were included. Results Of 339 patients, 264 (78%) received AC. There were no significant differences in median event-free survival (EFS) (7.0 vs. 7.5 years, P = .089) or overall survival (OS) (10 vs. 7.8 years, P = .11) between AC and non-AC groups. In the node-negative (ypN−) cohort (n = 169), there was no association between AC receipt and EFS (12 vs. 10 years, P = .7) or OS (12 vs. 10 years, P = .5). In the node-positive (ypN+) cohort (n = 170), AC receipt was associated with longer EFS (4.8 vs. 2.7 years, P = .031) but not OS (5.5 vs. 2.8 years, P = .071). High-risk patients based on lymph node ratio (LNR > 0.0685; n = 112) who received AC (n = 87; 78%) had longer EFS (P = .014) and OS (P = .033). Finally, AC receipt was associated with longer EFS (P = .014) and OS (P = .024) in those with incomplete/poor response to NAC (Becker tumor regression grade [TRG] 2-3). Conclusions AC following NAC was not associated with improved survival in resected ypN- GC. High LNR identified a ypN + subgroup in which AC receipt was associated with longer EFS and OS. In patients with incomplete/poor response to NAC (TRG 2-3), AC receipt was associated with longer EFS and OS.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.